Galozzi Paola, Bindoli Sara, Doria Andrea, Sfriso Paolo
Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy.
Biologics. 2022 Apr 21;16:21-34. doi: 10.2147/BTT.S290329. eCollection 2022.
Adult-onset Still's disease (AOSD) is a rare multifactorial autoinflammatory disorder of unknown etiology, characterized by an excessive release of cytokines triggered by dysregulated inflammation and articular and systemic manifestations. The clinical spectrum of AOSD ranges from self-limiting forms with mild symptoms to life-threatening cases and presents clinical and biological similarities with the juvenile form (sJIA). Nowadays, the advances in biologic agents no longer limit the treatment to NSAIDs, glucocorticoids, or conventional synthetic DMARDs. The blockade of IL-1 and IL-6 is effective in the treatment of systemic and articular inflammation of AOSD patients; however, novel compounds with different properties and targets are now available and others are being studied. In this review, starting from the pathogenesis of AOSD, we summarized the current and emerging biological therapies, possible effective agents for achieving AOSD control and remission.
成人斯蒂尔病（AOSD）是一种病因不明的罕见多因素自身炎症性疾病，其特征是炎症调节异常引发细胞因子过度释放，并伴有关节和全身表现。AOSD的临床谱从症状轻微的自限性形式到危及生命的病例不等，且在临床和生物学方面与幼年型（sJIA）存在相似之处。如今，生物制剂的进展不再将治疗局限于非甾体抗炎药、糖皮质激素或传统合成改善病情抗风湿药。阻断IL-1和IL-6对治疗AOSD患者的全身和关节炎症有效；然而，现在已有具有不同特性和靶点的新型化合物，还有其他化合物正在研究中。在本综述中，我们从AOSD的发病机制入手，总结了当前及新兴的生物治疗方法、实现AOSD控制和缓解的可能有效药物。
